FOLR1 and neoplasm: Notably, the antitumor activity of Tandem CAR-T cells exceeded that of FOLR1-CAR T cells (p <0.05, Figure 6E), and the tumor in one mouse was completely eradicated at day 28; the tumor did not recur through the end of the experiment (Figure 6B, D).